Barclays analyst Mark Devries downgrades Essent Gr (NYSE:ESNT) from Overweight to Equal-Weight and lowers the price target from $54 to $43.
Ainos, Inc. Announces 1-For-5 Stock Consolidation
Ainos, Inc. (NASDAQ:AIMD, AIMDW)))) ("Ainos," or the "Company"), a diversified healthcare company focused on the development of AI-powered point-of-care testing, VELDONA® low-dose interferon therapeutics, and
